I'm LongbridgeAI, I can summarize articles.Hong Kong’s 2026 corporate landscape is a stark reality check. Telecoms are grasping at AI lifelines, consumer brands are shedding weight to survive, and pharma is quietly expanding globally. Here is the unvarnished truth about who is actually making moves and who is faking it.
Let's be completely clear about what's happening in Hong Kong's market in mid-2026: it is a massive reality check. You have companies desperate to slap the 'AI' label on their aging operations, while former consumer darlings are finally realizing that infinite growth was always a myth.
Take Pop Mart (9992.HK). Legendary investor Duan Yongping saw his stake drop to 5.55% in August. The company insists it’s just derivative contract fulfillment, not an open-market dump. Right. Regardless of the spin, they are aggressively pushing physical stores from the Gold Coast to Taipei, still betting that plastic blind boxes are a viable global currency.
On the other side of the consumer coin, we have Jiumaojiu (9660.HK). They spent early 2026 doing exactly what they should have done sooner: shedding dead weight. With store counts shrinking and revenue down, they are desperately leaning on their Tai Er brand to keep the lights on. It’s pure survival mode. Then there's Fosun Tourism (6082.HK), which simply opted out of the public scrutiny altogether. They went private in 2025 because the market didn't care about their bloated 'super resort' strategy. Now they can pivot to an asset-light model without quarterly whining from shareholders.
Then we have the telecoms. Both PCCW (0008.HK) and HKT (6823.HK) are narrowing their losses—PCCW cut theirs to HKD 276 million in the first half of 2026. But suddenly, they are preaching about accelerating AI in their networks and gearing up for 6G in the Northern Metropolis. It’s the oldest trick in the book: when legacy telecom growth stalls, start speaking Silicon Valley. Meanwhile, hardware player Sunny Optical (2382.HK) is caught in an institutional tug-of-war, with BlackRock trimming and UBS adding. Everyone is waiting for a real catalyst.
The actual quiet winners? Old-school infrastructure and biotech. CSPC Pharmaceutical (6613.HK) just secured an FDA nod for an mRNA mpox vaccine and is pocketing a USD 10 million milestone payment from AstraZeneca. That is actual leverage, not a buzzword. Harbin Electric (1133.HK) is surfing the nuclear energy wave, teasing a massive 61.9% profit surge mid-year. As for heavyweights like Jiangxi Copper (0358.HK) and hydrogen-hopeful SinoHytec (2050.HK), they are simply keeping the industrial wheels turning.
The takeaway is obvious. Cut the fluff. The companies actually building pipelines and making real drugs are fine. The ones selling vibes and AI promises have a lot more to prove.